Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food ...
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Neovasc Inc. NVCN is a medical device company ...
Please provide your email address to receive an email when new articles are posted on . New data from the phase 2 COSIRA trial demonstrate that implantation of a coronary-sinus reducing device was ...
To accelerate recruitment of patients into the Trial, Neovasc is leveraging predictive machine learning technology from Komodo Health, to identify and engage healthcare practitioners (“HCP”) with ...
A new device, the Neovasc Reducer, is implanted in the coronary sinus vein using minimally invasive techniques. Placement of the device is performed using a procedure that is similar to implanting a ...
Please provide your email address to receive an email when new articles are posted on . In the phase 2 COSIRA trial, implantation of a coronary-sinus reducing device significantly improved symptoms ...
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results